Biomedicines, 2022 New more effective lipid-lowering therapies have made it important to accurately determine Low-density lipoprotein-cholesterol (LDL-C) at both high and low levels. LDL-C was measured by the β-quantification reference method (BQ) (N = 40,346) and compared
Maureen Sampson +8 more
doaj +1 more source
Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II [PDF]
, 2016 BACKGROUND: Many SNPs have been identified in genes regulating LDL-C metabolism, but whether their influence is similar in subjects from different ethnicities is unclear.
Beaney, KE +5 more
core +1 more source
Comparing calculated LDL-C with directly measured LDL-C in healthy and in dyslipidemic children
Clinical Biochemistry, 2017 LDL-C is one of the strongest markers for atherosclerosis and therapeutic decisions in children are based on its levels. Friedewald formula (FF) which is usually used for the calculation of LDL-C (cLDL-C); and Anandaraja's formula (AF) may under- or overestimate actual levels.To compare cLDL-C with directly measured LDL-C (dLDL-C) as a screening tool ...
Garoufi, A. +6 more
openaire +3 more sources
SWITCHING FROM STATIN MONOTHERAPY TO EZETIMIBE/SIMVASTATIN OR ROSUVASTATIN MODIFIES THE RELATIONSHIPS BETWEEN APOLIPOPROTEIN B, LDL CHOLESTEROL, ANC NON-HDL CHOLETEROL IN PATIENTS AT HIGH RISK OF CORONARY DISEASE [PDF]
, 2011 OBJECTIVE: To evaluate relationships between apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-HDL-C in high-risk patients treated with lipid-lowering therapy.
AVERNA, Maurizio +8 more
core +1 more source
Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. [PDF]
, 2019 High-dose statin (HDS) therapy is recommended to reduce low-density lipoprotein cholesterol (LDL-C); however, some patients are unable to tolerate the associated side effects. Nutraceuticals have shown efficacy in lowering LDL-C.
Cacciotti, L +8 more
core +1 more source
Revista de Ciências da Saúde Nova Esperança, 2005 Esta pesquisa foi realizada com o objetivo de avaliar os níveis sanguíneos de colesterol total, LDL-C, HDL-C e triglicérides. A população estudada foi selecionada a partir de uma amostragem aleatória simples, constituiu-se de 220 pacientes, sendo 102 do ...
Carolina Uchôa Guerra Barbosa +2 more
doaj +1 more source
Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis [PDF]
, 2017 Objectives Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes.
Caslake, Muriel +6 more
core +1 more source
Journal of Diabetes Research, 2015 Aims. To elucidate the levels of malondialdehyde-modified LDL (MDA-LDL)-related variables for predicting coronary artery stenosis (CAS) by coronary CT angiography (CCTA) in asymptomatic patients with type 2 diabetes (T2DM). Methods.
Kazuya Fujihara +13 more
doaj +1 more source
Assessing the Validity of Friedewald’s Formula and Anandraja’s Formula For Serum Ldl-Cholesterol Calculation [PDF]
Journal of Clinical and Diagnostic Research, 2015 Introduction: An important aspect of the assessment of cardiovascular risk for a dyslipidemic subject is the estimation of serum Low-Density Lipoprotein Cholesterol (LDL-C).
P. KRISHNAVENI, VANITHA MN GOWDA
doaj +1 more source
A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK®) lowering cardiovascular disease risk [PDF]
, 2018 Context: Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk.
Izzo, Raffaele +4 more
core +2 more sources